- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03760952 | Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling | completed | — | 242 | Immatics US, Inc.INDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02116530 | Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy | completed | Phase 3 | 401 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 28, 2025 |
| clinicaltrials |
| NCT04814667 | A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib(LAROTRACKING) | completed | — | 26 | Centre Leon BerardOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | completed | Phase 1 | 72 | Merus B.V.INDUSTRY | 4 | Dec 11, 2024 | clinicaltrials |
| NCT04020185 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | completed | Phase 1 / Phase 2 | 40 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05018273 | Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors | completed | Phase 1 | 26 | Nykode Therapeutics ASAINDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT05990920 | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | completed | Phase 1 | 6 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT00483366 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 13 | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03302325 | Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC | completed | — | 20 | Medical University of South CarolinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03516123 | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | CStone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03523819 | A Study of CS1002 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 91 | CStone PharmaceuticalsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03873883 | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer(IO-001) | completed | Phase 1 | 119 | iTeos TherapeuticsINDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05117177 | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | completed | Phase 1 | 57 | iTeos TherapeuticsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05131113 | Stratification of Patients in Oncogeriatrics and Personalization of Interventions(ONKO-FRAIL) | completed | N/A | 186 | Biogipuzkoa Health Research InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04538625 | Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy(OnTARGET) | completed | Phase 3 | 287 | Napo Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 26, 2024 | clinicaltrials |
| NCT03617692 | Cannabis Use in Cancer Patients | completed | — | 27 | University of Colorado, DenverOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | completed | Phase 1 | 91 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | completed | Phase 1 | 22 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04402606 | Study on Skin Toxicities Induced by Cancer Treatments(DERMACLIC) | completed | N/A | 292 | Institut CurieOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02054741 | Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer | completed | N/A | 733 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02107443 | Improving Communication in Older Cancer Patients and Their Caregivers(COACH) | completed | N/A | 546 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT00020371 | BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05078593 | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | completed | Phase 1 | 18 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03728179 | RACIN in Patients With Advanced TIL-negative Solid Tumors(RACIN) | completed | Phase 1 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05400265 | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor | completed | Phase 1 | 9 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01206465 | Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors | completed | Phase 1 | 29 | University of NebraskaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03941262 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | completed | Phase 1 | 27 | NKGen Biotech, Inc.INDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04811781 | Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study | completed | — | 761 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03274661 | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | completed | Phase 2 | 52 | Baptist Health South FloridaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT00084734 | Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | Roswell Park Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00107250 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | completed | Phase 1 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00357747 | AEG35156 and Docetaxel in Treating Patients With Solid Tumors | completed | Phase 1 | 10 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00372736 | AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | completed | Phase 1 | 27 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00390117 | AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00443976 | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT00504296 | SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 39 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00813423 | Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2023 | clinicaltrials |
| NCT00091169 | Levocarnitine in Treating Fatigue in Cancer Patients | completed | Phase 3 | 376 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00003266 | Methylphenidate in Treating Patients With Melanoma | completed | Phase 3 | 200 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT00002520 | Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer | completed | N/A | 434 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05518799 | CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours | completed | N/A | 18 | The Netherlands Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04084951 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | SQZ BiotechnologiesINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2025source: clinicaltrials